The study was to evaluate the effect of the dietary supplement BreastDefend (BD) on the proliferation and invasive behavior of highly metastatic human breast cancer cells in vitro. Methods: Cell proliferation and cytotoxicity of BD was evaluated in MDA-MB-231 cells treated with BD (0-40 μg/mL) by MTT assay and trypan blue staining, respectively. Expression of cell cycle regulatory genes were determined by DNA-microarray analysis. Effect of BD on invasiveness was assessed by cellular adhesion, migration, and invasion assays. Results: BD treatment of cells MDA-MB-231 resulted in the cytostatic inhibition of cell proliferation with IC 50 22.2, 19.1, and 17.5 μg/mL for 24, 48, and 72 hours, respectively. The inhibition of proliferation was mediated by the upregulation expression of CCNG1, CHEK1, CDKN1C, GADD45A, and E2F2, whereas BD downregulated expression of CCNA1 and CDK6 genes. The induction of expression of GADD45A and inhibition of expression of cyclin A1 (gene CCNA1) by BD was also confirmed on the protein level. BD treatment suppressed the invasive behavior of MDA-MB-231 cells by the inhibition of cellular adhesion, migration, and invasion. This inhibition of invasiveness was mediated by the suppression of secretion of urokinase plasminogen activator (uPA), and by the downregulation of expression of CXCR4 in breast cancer cells treated with BD. Conclusion: BD inhibits proliferation and invasive behavior of the highly metastatic human breast cancer cells in vitro. BD may have a therapeutic potential for prevention or treatment of highly metastatic breast cancers.
Introduction
Regardless of the fact that breast cancer mortality decreased by 22 .9% from 1991 to 2003, breast cancer remains the leading cause of cancer death among 20-to 59-year-old U.S. women with estimated 40 170 new deaths in 2009. 1 The high mortality of patients with breast cancer is linked to the invasive behavior of cancer cells resulting in the cancer metastasis. Cancer metastasis consist of several interdependent processes such as uncontrolled growth of cancer cells, their invasion into surrounding tissues and blood vessels, cell migration, adhesion, and invasion, finally resulting in the colonization of other organs and tissues. 2 Therefore, in addition to the standard chemotherapy of metastatic breast cancers, the development of new natural antiproliferative and antimetastatic nontoxic agents is required. 3 Recent epidemiological studies from Asia demonstrated inverse correlation between mushroom intake and gastric, gastrointestinal, and breast cancer. [4] [5] [6] [7] Moreover, different dietary phytochemicals have demonstrated cancer chemopreventive activities in tissue culture and animal studies. 8 For example, quercetin downregulated expression of Her-2, tyrosine kinase receptor, which is overexpressed in breast cancers. 9 In addition to the inhibition of specific target molecules in cancer cells, antioxidant activity of curcumin was associated with its cancer preventive properties in a variety of cancers. 10 Diindolylmethane (DIM) specifically inhibited growth of breast cancer cells via activation of p27kip, inhibitor of cell cycle progression, independently of Her-2, Akt, or estrogen receptor status, thereby suggesting its chemoprevention potential in breast cancer. 11 Therefore, the combination of natural compounds with specific activities can be used for the development of dietary supplements against cancer. BreastDefend (BD) is a novel dietary supplement containing a blend of medicinal mushrooms (Coriolus versicolor, Ganoderma lucidum, Phellinus linteus), medicinal herbs (Scutellaria barbata, Astragalus membranaceus, Curcuma longa), and purified biologically active nutritional compounds (diindolylmethane, quercetin).
In the present study, we evaluated the effect of BD on the highly invasive and metastatic human breast cancer cells MDA-MB-231. We used DNA-microarray analysis to determine which genes are associated with the growth suppression of MDA-MB-231 cells treated with BD. Here, we show that BD inhibits proliferation and modulates expression of cell cycle regulatory genes. In addition, BD also suppresses invasive behavior of MDA-MB-231 cells by the inhibition of cell adhesion, migration, and invasion. In summary, this study demonstrates the mechanisms employed in the inhibition of growth and invasive behavior of breast cancer cells by the dietary supplement BreastDefend.
Materials and Methods

Cell Culture and Reagents
Highly invasive human breast cancer cells (MDA-MB-231) were obtained from ATCC (Manassas, VA). MDA-MB-231 cells were maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with penicillin (50 U/mL), streptomycin (50 U/mL), and 10% fetal bovine serum (FBS). Media and supplements came from GIBCO BRL (Grand Island, NY). FBS was obtained from Hyclone (Logan, UT). BreastDefend (BD) was supplied by the EcoNugenics, Inc (Santa Rosa, CA). BD contains the following active components by weight: herb and active nutritional blend 57.56% (quercetin, 98% bioflavonoids; turmeric rhizome extract complex with enhanced bioavailability, BCM-95, 95% curcumin; S barbata herb extract; and A membranaceus root extract), a blend of dried and milled whole body mycelium (the vegetative hypoallergenic stage of the life cycle of fungi, as opposed to the spore contain sexual stage, fruiting bodies or an extract) mushroom blend 30.3% (3 parts P linteus:1 part C versicolor:1 part G lucidum), and diindolylmethane 12.12%. BD stock solution was prepared by dissolving BD in dimethylsulfoxide (DMSO) at a concentration 25 mg/mL and stored at 4°C.
Cell Proliferation and Cell Viability Assays
Cell proliferation was determined by the tetrazolium salt method, according to the manufacturer's instructions (Promega, Madison, WI). Briefly, cancer cells were cultured in a 96-well plate and treated for indicated times with BD (0-40 µg/mL). At the end of the incubation period, the cells were harvested and absorption was determined with an ELISA plate reader at 570 nm, as previously described. 12 Cell viability of MDA-MB-231 cells was determined after incubation with BD (0-40 µg/mL) for 24 hours by staining with trypan blue as previously described. 13 Data points represent mean ± SD in the representative experiment of triplicate determinations. Similar results were obtained in 2 independent experiments.
DNA Microarrays
MDA-MB-231 cells were treated with BD (30 µg/mL) or 0.2% DMSO for 24 hours and total RNA isolated with RNAeasy (Qiagen, Valencia, CA). This RNA was used to generate cDNA and biotinylated-labeled cRNA probes. The resulting cRNA probe (3 µg) was hybridized to each cell cycle specific Oligo GEArray membrane that contained a total of 112 cell cycle regulatory genes. The hybridization signal was detected by chemiluminescent detection kit (SABiosciences, Frederick, MD), as previously described. 14 The array images were scanned using a HP Professional Scanner (Hewlett-Packard, Palo Alto, CA) and 2 independent microarrays were performed to verify the reproducibility of experimental results.
Microarray Data Analysis
The microarray image of each gene was analyzed by GEArray expression analysis suite (SABiosciences). The gene expression levels of each array were normalized to selected genes (β-actin) and background of each spot was corrected with minimum value of array spot. The changes in gene expression between control and treatment groups were distinguished by a ratio of BD treatment group/control group. If the ratio was >1, it indicated that BD treatment increased mRNA expression level of each gene. If the ratio was <1, it indicated that BD treatment decreased mRNA expression level. The following was defined: If ratio was ≥1.4-fold or ≤0.6-fold, the difference in gene expression between control and BD treatment group was considered significant. The gene expression levels and functions were illustrated by a visualization tool, GenMAPP. The differential gene expression between control and BD treatment was defined as follows: ratio ≥1.4 (upregulated); ratio ≤0.6 (downregulated); ratio between 1.4 and 0.6 (no criteria met); ratio = 0 (not found).
Cell Adhesion, Migration, and Invasion Assays
Cell adhesion of MDA-MB-231 cells, treated with BD (0-40 µg/mL) for 24 hours, was evaluated with Cytomatrix Adhesion Strips coated with human fibronectin (Chemicon International, Temecula, CA) as previously described. 15 Briefly, MDA-MB-231 cells were treated with BD (0-40 µg/mL) for 24 hours, harvested and cell adhesion was determined after 1.5 hours of incubation at 37°C. Cell migration of MDA-MB-231 cells treated with BD (0-40 µg/ mL) was assessed in Transwell chambers as previously described. 16 Invasion of MDA-MB-231 cells treated with BD (0-40 µg/mL) was assessed in Transwell chambers coated with 100 µL of Matrigel (BD Biosciences, Bedford, MA) as previously described. 16 Western Blot Analysis MDA-MB-231 cells were treated with BD (0-40 µg/mL) for 24 hours, whole cell extracts were isolated, and Western blot analysis performed as described. 17 The corresponding primary antibodies anti-β-actin, anti-cyclin A1, anti-COX-2, anti-GADD45A, (Santa Cruz Biotechnology, Santa Cruz, CA), anti-MMP-9 (Cell Signaling Technology, Danvers, MA), and anti-CXCR4 (Millipore, Temecula, CA) were used for the detection of specific proteins. Secretion of urokinase plasminogen activator (uPA) into media of MDA-MB-231 treated with BD (0-40 µg/mL) for 24 hours was detected by Western blot analysis as previously described. 18 
Statistical Analysis
Data are expressed as the mean ± standard deviation (mean ± SD) of 3 experiments. Minitab statistical software for Windows (Minitab, Inc., State College, PA) was used for statistical analysis. Statistical differences between means were evaluated using a one-way analysis of variance (ANOVA) followed by Tukey's pairwise comparisons. P < .05 was considered significant.
Results
BD Inhibits Proliferation of Highly Invasive Breast Cancer Cells
Because invasive behavior of breast cancer cells is directly associated with their metastatic potential resulting in the high cancer mortality of cancer patients, we evaluated whether BD inhibits growth of highly invasive (MDA-MB-231) breast cancer cells. As seen in Figure 1A , increased concentration of BD (0-40 µg/mL) markedly suppressed the proliferation of MDA-MB-231 in a dose-and time-dependent manner. The IC 50 of BD for 24-, 48-, and 72-hour treatment was 22.2, 19.1, and 17.5 µg/mL, respectively. To determine if the effect of BD on cancer cells is cytotoxic or cytostatic, we evaluated the cell viability after 24 hours of BD treatment. The viability of MDA-MB-231 cells in the control group (0 µg/mL BD), was essentially the same as in the cells treated with the highest concentration of BD (40 µg/mL; Figure 1B ), whereas 40 µg/mL of BD inhibited proliferation by 78% ( Figure 1A ). Therefore, these data suggest that the BD inhibits growth of breast cancer cells predominantly through a cytostatic effect.
Effect of BD on Cell Cycle Regulatory Genes
To identify genes responsible for the cytostatic effect of BD breast cancer cells we used cDNA microarray analysis with key cell cycle regulatory genes. MDA-MB-231 cells were treated with BD (30 µg/mL) for 24 hours and cDNA microarray analysis was performed as described in the Materials Table 1 , BD modulated the expression of nine cell cycle regulatory genes (CCNA1, CCNG1, CDK6, CDKN1C, CDKN2C, CHEK1, GADD45A, E2F2, and MCM7). Among them, BD significantly induced expression of CCNG1, CHEK1, CDKN1C, GADD45A, and E2F2, whereas BD markedly downregulated expression of CCNA1 and CDK6 genes in breast cancer MDA-MB-231 cells. To visualize our expression data in the context of cell cycle pathway, we drew a cell cycle pathway to illustrate the different expression and function of several critical genes of cell cycle regulatory genes (Figure 2A ). Furthermore, we have confirmed expression of some cell cycle regulatory genes on the protein levels. MDA-MB-231 cells were treated with BD (0-40 µg/mL) for 24 hours, whole cell extracts prepared and Western blot analysis performed. Consistent with the DNA microarray data, BD markedly induced expression of the DNA damage inducible protein GADD45A, which induces the cell cycle growth arrest, 19 and downregulated expression of cyclin A1 (gene CCNA1), which regulates cell mitosis through its binding to cell cycle regulators such are the Rb family of proteins, the transcription factor E2F-1, and the p21 family of proteins 20 ( Figure 2B) . Thus, the DNA microarray and Western blot analyses confirm that BD suppresses proliferation of human breast cancer cells MDA-MB-231 through the upregulation of expression of GADD45A and inhibition of expression of cyclin A1.
BD Suppresses Invasive Behavior of Breast Cancer Cells
Invasive behavior of cancer cells results in cancer metastasis and is directly associated to cell adhesion, migration, and invasion. Integrin receptor α 3 β 1 controls cell adhesion of breast cancer cells through its interaction with the ECM protein fibronectin. 21 To evaluate if BD affects adhesion of invasive breast cancer cells, MDA-MB-231 cells were treated with BD (0-40 µg/mL) for 24 hours and adhesion to fibronectin was determined. As seen in Figure 3A , BD treatment at 40 µg/mL concentration significantly suppressed adhesion of MDA-MB-231 cells by 47.6%. The effect of BD on cell migration was assessed in MDA-MB-231 cells treated with BD (0-40 µg/mL) as described in the Materials and Methods section. BD treatment markedly suppressed migration of breast cancer cells in a dose-dependent manner by 38.8% and 48.0% with 20 and 40 µg/mL of BD, respectively ( Figure 3B ). Finally, we evaluated the effect of BD on cell invasiveness. MDA-MB-231 cells were plated on Matrigel-coated filters in the presence of BD (0-40 µg/ml) and the amount of cells invaded through Matrigel determined as described in the Materials and Methods section. A significant 21.4% and 26.2% inhibition of invasion by BD was observed with 20 and 40 µg/mL of BD, respectively ( Figure 3C ). Taken together, BD suppresses invasive behavior of metastatic breast cancer cells through the suppression of cell adhesion, migration, and invasion.
BD Inhibits Secretion of Urokinase Plasminogen Activator (uPA) and Downregulates Expression of CXCR4 in Breast Cancer Cells
Invasive behavior of breast cancer cells is associated with the increased expression of the serine protease uPA. 22 Moreover, increased levels of uPA were detected in patients with breast cancer and higher levels of uPA were correlated with negative prognosis. 23 Therefore, we evaluated whether BD affects secretion of uPA from breast cancer cells. MDA-MB-231 cells were treated with BD (0-40 µg/mL) for 24 hours and uPA secretion evaluated by Western blot analysis in conditioned media. In agreement with our data demonstrating that BD inhibits cell adhesion, migration, and invasion, the secretion of uPA from MDA-MB-231 cells was markedly inhibited by BD treatment (Figure 4A ). Moreover, matrix metalloproteinase MMP-9, chemokine receptor CXCR4, and cyclooxygenase-2 (COX-2) were also associated with invasiveness of breast cancer cells. [24] [25] [26] To evaluate whether BD affects expression of these proteins, MDA-MB-231 cells were treated with BD (0-40 µg/mL) and whole cell extracts subjected to Western blot analysis Integrative Cancer Therapies 10(2) with specific antibodies against MMP-9, CXCR4, and COX-2. As seen in Figure 4B , the expression of CXCR4 was markedly suppressed by BD treatment in a dose response manner, whereas the levels of MMP-9 and COX-2 were not affected by the BD treatment. Therefore, BD suppresses invasive behavior of breast cancer cells by the inhibition of secretion of uPA and by the downregulation of expression of CXCR4.
Discussion
In the present study, we evaluated the effect of dietary supplement BD on highly invasive and metastatic human breast cancer cells MDA-MB-231. Here, we show that BD suppressed cell proliferation of MDA-MB-231 cells through its cytostatic effect. As mentioned above, BD is a mixture of medicinal mushroom mycelium, herbs and biologically active compounds. Some of these isolated components of BD previously demonstrated direct cytotoxic effect on breast cancer cells. For example, extracts from medicinal mushrooms C versicolor and G lucidum, 27, 28 medicinal herbs S barbata, A membranaceus, and C longa, [29] [30] [31] and nutritional compounds diindolylmethane and quercetin 32, 33 induced apoptosis in breast cancer cells, respectively. Nevertheless, the cytotoxic activities of some isolated extracts were achieved at higher concentrations with IC 50 in the range of 72 to 514 µg/mL for MDA-MB-231 cells, 27, 28 whereas BD demonstrated cytostatic effect for the same cell line at markedly lower concentrations with IC 50 22 µg/mL. Therefore, the combination of different compounds in BD can increase the biological activity of particular compound at lower dose, and instead of cytotoxic effect can cause cytostatic cell cycle arrest. In addition, the lower doses of particular compounds could result in the physiologically relevant concentrations of these compounds in combination.
Here we show that the inhibition of proliferation of breast cancer cells by BD was associated with the upregulation of expression of CCNG1, CHEK1, CDKN1C, GADD45A, and E2F2, and the downregulation of expression of CCNA1 and CDK6 genes in MDA-MB-231 cells. We also imported expression data into the GenMAPP program, a powerful visualizing tool, to demonstrate the cell cycle pathway altered by BD. Our GenMAPP map clearly showed that BD significantly modulated the expression of several genes involved in G1 and S phase (CCNA1, CDK6, CDKN1C, and E2F2). Therefore, our data are in agreement with previous reports demonstrating that the induction of cell cycle arrest of breast cancer cells is associated with increased expression of cyclin G1, CHEK1, CDKN1C (p57, Kip2), GADD45A, and E2F2. [34] [35] [36] [37] [38] In addition, cycle arrest of MDA-MB-231 cells can be mediated by the inhibition of cyclin A1 and CDK6. 39, 40 In this study, we found that BD suppresses invasive behavior of MDA-MB-231 cells. This observation is in agreement with our previous studies where we demonstrated inhibition of invasiveness of human breast cancer cells with extracts from medicinal mushrooms G lucidum and P linteus. 16, 41 In addition, PSK, a protein-bound polysaccharide from the mushroom C versicolor, suppressed tumor invasion and metastasis in different animal models. 42 An extract from A membranaceus combined with Salvia miltiorrhiza (CASE) inhibited cell invasion of hepatoma cells, 43 whereas purified curcumin, diindolylmethane, and quercetin suppressed invasiveness of breast cancer cells. [44] [45] [46] As previously reported, G lucidum and P linteus suppressed invasiveness of breast cancer cells; however, their concentrations were significantly higher than the concentration of BD used in the current report, suggesting that the combination of different compounds in BD can markedly increased its biological activity. 16, 41 The inhibition of invasive behavior of MDA-MB-231 cells by BD in our study was associated with the suppression of secretion of uPA and the downregulation of expression of CXCR4. This observation is in agreement with other studies demonstrating that G lucidum and P linteus inhibit uPA, 16, 41 and diindolylmethane suppresses uPA and CXCR4 in breast cancer cells. 47 In conclusion, dietary supplement BD demonstrated significant inhibition of growth and invasive behavior of highly metastatic human breast cancer cells in vitro through the suppression of specific target molecules. Our data study suggests the therapeutic use of BD in the treatment of highly invasive breast cancers. Further studies evaluating the biological activity of BD in an animal model of human breast cancer are in progress.
